I TALIIAN authors reported' that daily oral administration of 250 mg. of /-benzal butyramide* reduced significantly the concentration of serum cholesterol in man. Previ-ously it was reported that the substance inhibited "in vitro" cholesterol synthesis,2 anid the incorporation of C14-l-acetate and C14-2-mevalonate into cholesterol. 3 ported to reduce Triton-induced hypereholesteremia in rats4 as well as estrogen-induced hypercholesteremia in fowl.5
Material and Methods Fifteen patients were studied in 32 experimental periods of 4 to 13 weeks. Five patients were male and 10 were female, with an age range of 34 to 78 years. The food intake of the patients was uncontrolled, but they were instructed to adhere to their customary diets. Patients were weighed weekly, and blood counts, tests of urine, blood urea nitrogen, blood sugar, serum bilirubin, serum transamiinase, and cephalin flocculation were carried out periodically.
Total serum cholesterol concentrations were determined once a week in the fasting state by the imethod of Abell et al. 6 The control serum cholesterol levels, prior to the administration of the drug, were observed for periods of 6 weeks or longer. Average control cholesterol concentrations were higher than 300 mg. per cent in 10 of the 15 subjects studied. Serum eholesterol concentrations were determined in nine patients for 6 to 14 weeks after the experimental medication was dis-
Results
The results of the oral administration of /-benzal butyramide are ineluded in table 1. There was no noticeable difference in serum cholesterol coneentrations during the admiinistration of different doses of the drug as compared to control periods. The weight of the patients remained within the limit of 2 lbs. variation. No major side effects were noted during the administration of the drug as determined by the previously described laboratory tests. One patient developed marked headaches during the study, which probably cannot be attributed to 3-benzal butyramide. continued. /-benzal butyramide was given orally in two divided doses, at daily dose levels of 250 leg., 500 mg., and 2 Gm. for periods of 4 to 13 weeks each.
Conclusions
The oral administration of /-benzal butyramide, at daily dose levels of 250 mg., 500 mg., and 2 Gm. for 4 to 13 weeks each, failed to influence serunm cholesterol concentrations in 10 hypercholesteremic and five normocholesteremic patients.
